acid-phosphatase and Urination-Disorders

Topics: Acid Phosphatase; Bone and Bones; Bone Neoplasms; Histocytochemistry; Humans; Hydronephrosis; Immunodiffusion; Lymphatic Metastasis; Male; Prostate; Prostatic Neoplasms; Radiography; Radionuclide Imaging; Urination Disorders

Seventy-two patients with advanced prostatic carcinoma without previous endocrine therapy were treated with an oral nonsteroidal antiandrogen, flutamide. Sixty-three patients (87.5%) had a favorable response, and 9 patients showed no response. Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy.

Topics: Acid Phosphatase; Adenocarcinoma; Adult; Aged; Anilides; Bone Neoplasms; Clinical Trials as Topic; Flutamide; Humans; Hydronephrosis; Male; Middle Aged; Prostatic Neoplasms; Soft Tissue Neoplasms; Urination Disorders

Clinical and statistical investigations were performed on 157 patients with prostate carcinoma in the Third Teaching Hospital, Normal Bethune University experienced between January, 1950 and June, 1986. The number of patients with prostate carcinoma among other hospitalized patients showed a recent gradual increase. The patient's age at the time the disease was first diagnosed was most frequently between 60 and 69 years old with an average age of 63.3 years. Dysuria was the most prominent symptom, followed by frequency, retention and macroscopic hematuria. Duration between initial symptom and diagnosis was one to two years in most patients. The prostatic abnormality could be detected by rectal examination in all patients. Elevation of serum acid phosphatase was found in 24.4%. Such elevation was evident in 52.2% of the patients with metastatic lesions, compared to 14.4% of those without metastasis. Fourteen patients had metastasis to bone (8.9%), 13 to lymph nodes, 2 to lung and one to liver. According to the staging diagnosis, 19 patients (12.1%) had stage A, 78 patients (49.7%) had stage B, 20 patients (12.7%) had stage C and 40 patients (25.5%) had stage D carcinoma. Histological findings in 57 patients indicated adenocarcinomas; 39 cases (68.4%) were poorly differentiated, 12 cases (21.2%) were moderately differentiated and 6 cases (10.5%) were well differentiated. Modality of treatment was total prostatectomy in 2 cases (1.3%), antiandrogen therapy (orchiectomy and/or Stilbestrol) in 122 cases (77.7%), subcapsular prostatectomy in 7 cases (4.5%), symptomatic treatment in 5 cases and no treatment in 23 cases (14.6%).

Topics: Acid Phosphatase; Adenocarcinoma; Adult; Aged; Aged, 80 and over; China; Combined Modality Therapy; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms; Urination Disorders

Since 1981 we have been studying prostate cancer (Pca) by mass screening in three cities, eight towns and seven villages in Gunma prefecture, Japan. From 1981 to 1985, 5,770 subjects were examined. The clinical character of Pca detected by mass screening is compared with control (i.e., Pca detected in the outpatient clinic in Gunma University). Of the 54 Pca patients detected by mass screening (Stage B: 28, C: 8, D: 18), approximately 50% had early-stage Pca. The ratio of early-stage Pca is significantly higher than in the control. An extended survival rate in high-stage Pca detected by mass screening also was observed through comparison with control. We determined two types of Pca in advanced stage: (1) asymptomatic or less symptomatic and better prognostic Pca found in mass screening and (2) symptomatic and worse prognostic Pca found in control.

Topics: Acid Phosphatase; Aged; Aged, 80 and over; Biopsy; Gait; Humans; Japan; Male; Mass Screening; Middle Aged; Pain; Palpation; Prognosis; Prostatic Neoplasms; Surveys and Questionnaires; Urination Disorders

A prospective study of serum prostatic acid phosphatase (PAP) levels in benign prostatic disease is reported. In 12 patients with acute retention the initial PAP level when compared with the level twenty-four hours after catheterization showed a significant fall (p less than 0.02). The initial PAP level was raised above the upper limit of normal in 7 patients (in 3 markedly so, of whom 2 had subsequent histologic evidence of prostatic infarction). In 10 patients with chronic retention there was a significant rise in the PAP level twenty-four hours after catheterization, but in only 1 case did this exceed the normal range. We discuss the significance of a raised PAP level in patients with acute retention and suggest that it may indicate a group of patients in whom the etiology of acute retention is spontaneous prostatic infarction and subsequently may require different management.

Topics: Acid Phosphatase; Acute Disease; Aged; Chronic Disease; Humans; Male; Prospective Studies; Prostate; Prostatectomy; Prostatic Hyperplasia; Urination Disorders

D-Trp-6-LH-RH, a long acting LH-RH agonist was given in a phase II trial to 85 patients aged 52 to 88 (mean 69) with advanced prostatic carcinoma, stage B (8 pts), C (9 pts) and D (68 pts). Twenty-five patients were previously untreated, 40 had received previous hormonal therapy but none was considered has having hormone resistant tumor; 20 patients had received surgery or radiotherapy or both. D-Trp-6-LH-RH was given s.c. at a daily dose of 500 micrograms during the first seven days, followed by 100 micrograms daily. Antitumor activity was assessed after 90 days and treatment was continued in responders. The results were the following: plasmatic levels of LH were sharply decreased and those of testosterone were in all cases under 1 ng/ml by the 90th day of treatment; urinary symptoms and bone pain disappeared or were greatly improved in almost all patients; the volume of the prostate measured by ultrasonography and/or computerized tomography regressed by more than 50% of initial volume in 44% of the 34 patients for which this parameter was evaluable; bone scintiscans were improved in 18% of evaluable patients; plasmatic levels of prostatic acid phosphatases determined by radio immuno-assay were elevated in 28 patients, 61% of which presented a decrease superior to 50% or normalisation of this parameter. No disease flare up was observed on initiation of therapy. Impotence was constant but reversible on discontinuation of therapy. No other side effect could be attributed to therapy.

Topics: Acid Phosphatase; Aged; Aged, 80 and over; Bone Neoplasms; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms; Triptorelin Pamoate; Urination Disorders

Fourteen patients with locally recurrent prostate carcinomas after external beam irradiation received 135I seed implants at Stanford between 1975 and 1979. Clinical local control has been obtained in 11 of the 14 patients for follow-up periods of 6 to 36 months. Eight remain without evidence of disease, but 2 of the 3 patients whose pelvic lymph nodes were involved by carcinoma have developed distant metastases. Complications, consisting of either cystoproctitis, urinary incontinence, or the development of a vesicorectal fistula occurred in 4 of the 14 patients. These complications were noted only in those patients who had implantation of high intensity 125I seeds (greater than 0.50 mCi) into large prostatic volumes (greater than or equal to 50 cc). No complications occurred in patients who received lower intensity 125I seed implants in smaller prostatic volumes. We conclude that 125I seed implants may be used in a second attempt to obtain local control after a local relapse following external beam irradiation, if the use of high intensity 125I sources and/or the implantation of large prostate volumes are avoided.

Topics: Acid Phosphatase; Brachytherapy; Diethylstilbestrol; Dose-Response Relationship, Radiation; Follow-Up Studies; Humans; Iodine Radioisotopes; Lymph Node Excision; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostatic Neoplasms; Urination Disorders

Topics: Acid Phosphatase; Biopsy; Hematuria; Humans; Male; Middle Aged; Palpation; Prostatic Neoplasms; Urination Disorders

Topics: Acid Phosphatase; Acute Kidney Injury; Aged; Carcinoma; Cryosurgery; Humans; Male; Middle Aged; Postoperative Complications; Prostatic Neoplasms; Rectal Fistula; Urinary Fistula; Urinary Incontinence, Stress; Urination Disorders

Prostatic infarction is a relatively frequent complication of adenoma of the bladder neck. Nevertheless its importance is minimal as compared with infarctions of vital organs like the brain, heart, lungs or kidneys. General and local factors may play a role in its pathogenesis. Besides other factors, it may contribute to the development of acute retention. Attention is called to the difficulties of differential diagnosis at both gross and microscopic examinations. A misdiagnosis is most frequently made in neoplastic diseases of the prostate.

Topics: Acid Phosphatase; Adenoma; Aged; Diagnosis, Differential; Humans; Infarction; Male; Middle Aged; Prostate; Urinary Bladder Neoplasms; Urination Disorders

Topics: Acid Phosphatase; Aged; Biopsy; Breast Neoplasms; Carcinoid Tumor; Castration; Diethylstilbestrol; Humans; Male; Mastectomy; Neoplasm Metastasis; Prostatic Neoplasms; Urination Disorders

Topics: Acid Phosphatase; Age Factors; Aged; Blood Sedimentation; Diagnosis, Differential; Estrogens; Hemoglobins; Humans; Male; Middle Aged; Prognosis; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies; United Kingdom; Urea; Urination Disorders

Topics: Acid Phosphatase; Aged; Antigens, Neoplasm; Blood Urea Nitrogen; Bone Neoplasms; Cryosurgery; Follow-Up Studies; Humans; Hydronephrosis; Immunoglobulins; Male; Middle Aged; Neoplasm Metastasis; Pain Management; Palliative Care; Postoperative Complications; Prostate; Prostatic Neoplasms; Time Factors; Urinary Tract Infections; Urination Disorders

Topics: Acid Phosphatase; Aged; Biopsy; Estrogens; Humans; Male; Methods; Middle Aged; Prostate; Prostatectomy; Prostatic Neoplasms; Urination Disorders

Topics: Acid Phosphatase; Chlorotrianisene; Diethylstilbestrol; Humans; Injections, Intravenous; Male; Neoplasm Metastasis; Neoplasms; Palliative Care; Prostatectomy; Prostatic Neoplasms; Toxicology; Urination Disorders

Topics: Acid Phosphatase; Clinical Enzyme Tests; Diagnosis; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Urinary Catheterization; Urination Disorders

Topics: Acid Phosphatase; Alkaline Phosphatase; Carcinoma; Castration; Dithizone; Estrogens; Humans; Indicators and Reagents; Male; Neoplasms; Orchiectomy; Pancreas; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Research; Retina; Semen; Spermatozoa; Testosterone; Toxicology; Urination Disorders; Zinc